España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Appili Therapeutics
APLIF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.0199
-0.00330
-14.22%
Pre-Market: Dec 28, 4:00 PM EDT
Get Report
Comment
Appili Therapeutics (APLIF) Forecast
News
Earnings
Appili Therapeutics (APLIF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Appili Therapeutics (OTC:APLIF) Stock
Appili Therapeutics Stock (OTC: APLIF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, August 21, 2024
Aditxt's Adivir, Inc., Agreed To Acquire All ...
Benzinga Newsdesk
Thursday, July 25, 2024
Aditxt Signs Second Amendment To The Arrangem...
Benzinga Newsdesk
Tuesday, September 06, 2022
APLIF: Advancing Multiple Programs to Combat Infectious Diseases…
Zacks Small Cap Research
Thursday, July 14, 2022
APLIF: New Late Stage Program to Treat Cutaneous Leishmaniasis…
Zacks Small Cap Research
Thursday, March 03, 2022
APLIF: U.S. DoD to Provide Over US$10 Million in Funding for ATI-1701…
Zacks Small Cap Research
Tuesday, December 28, 2021
Aditxt Signs Share Exchange Agreement to Acquire AiPharma in Cash, Stock Deal
Charles Gross
Monday, November 29, 2021
APLIF: PRESECO Trial Unsuccessful in COVID-19…
Zacks Small Cap Research
Friday, November 05, 2021
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
Dana Salzarulo
-
Sponsored
Thursday, October 28, 2021
Is Pfizer Conceding Race in Hospitalized Covid Because of Todos Medical's Triple MOA Antiviral?
Dana Salzarulo
-
Sponsored
Tuesday, October 05, 2021
Aditxt Shares Surge On AiPharma Acquisition, Holder Of COVID-19 Candidate
Vandana Singh
Wednesday, September 01, 2021
APLIF: Awaiting Data Readout for Phase 3 PRESECO Trial in COVID-19…
Zacks Small Cap Research
Monday, June 28, 2021
APLIF: DSMB Recommends for PRESECO Trial to Complete; Data Expected in 3Q21…
Zacks Small Cap Research
Monday, May 03, 2021
Appili Pharmaceuticals ($APLIF): The Last COVID-19 Stock With Massive Upside - Under $50 Million Market Cap
Willow Research
Tuesday, November 24, 2020
Health Canada Clears Appili Therapeutics For ...
Benzinga Newsdesk
Friday, October 30, 2020
Appili Therapeutics Signs Collaboration, Deve...
Benzinga Newsdesk
Monday, August 10, 2020
FDA Clears Appili Therapeutics to Expand its ...
Luke J Jacobi
